Key Takeaways
- Cycle bottom called, recovery bets placed: Management believes derivative prices and caustic realizations have bottomed out in Q3, with positive signs emerging from Q4 onwards, though the worst chemical environment in 15 years extended one quarter longer than expected.
- Volume engine running on new capacities: 18% YoY volume growth in Q3 was driven by Epichlorohydrin and CPVC Resin, both commissioned in FY23, with Epichlorohydrin utilization now ramping from 40-45% to 55-60%.
- Specialty mix shift protecting the P&L: Revenue from derivatives and specialty segment rose to 42% of nine-month FY24 revenue from 27% a year ago, helping the company withstand a challenging pricing environment.
- Peak debt, peak CapEx, inflection ahead: Debt of ~₹940 crore is at its peak; as new capacities complete and start contributing cash flows from next year, the balance sheet begins to delever while still funding ~₹300-350 crore of annual CapEx.
- What to watch next quarter: Whether the Q4 pricing recovery actually materializes across derivatives, the pace of Epichlorohydrin and CPVC new capacity ramp-ups, and any progress on the Chlorotoluene project commissioning timeline.
Demand & Pricing Environment
- Cycle extended, not broken: The worst chemical downcycle in 15 years, initially expected to last through H1, extended into Q3 before showing signs of bottoming. Management sees positive demand and inventory movement signals from Q4.
- Derivative prices at floor: Management believes all derivative prices have almost bottomed out in Q3, citing current energy cost levels as the anchor; positive impact is expected from Q4 onwards.
- Caustic realizations stable at lows: Realizations have held in the ₹31,000-₹32,000 range despite demand pressure and ample supply; management views this range as bottomed out, with improvement timing uncertain.
- Textile segment recovering: Textile has recovered to 90-95% after Diwali; other segments expected to start moving up from January.
- Europe in reverse: European producers are running at 60-65% capacity due to high energy costs and weak downstream demand; no additional export demand is flowing to Asia as a result.
- Energy cost asymmetry: Energy prices have fallen but not to pre-COVID levels, and the drop has not been proportionate to the decline in Chlor-Alkali realizations, pressuring margins.
Maulik Patel: "We feel that that was extended one more quarter up to Q3 and probably from Q4 we are seeing some positive sign in terms of the recovery of the demand on started moving the inventory at least."
Volume Growth & Capacity Ramp-Up
- New products driving volumes: 18% YoY volume growth in Q3 and 17% for nine months came majorly from Epichlorohydrin and CPVC Resin, both commissioned in FY23. Continuous CapEx in prior years built the base and diversified the customer mix.
- Epichlorohydrin ramp on track: Capacity utilization improved from 40-45% last quarter to 55-60% currently, in line with the estimated ramp-up plan, with further improvement expected from Q4.
- CPVC Resin running at ~85% utilization: Realization around ₹140; new 45,000-ton capacity addition will drive further volume growth.
- CPVC compound forward integration: The new 35,000-ton CPVC compound facility is a forward integration of CPVC Resin, targeting the ~20% of customers who prefer compound directly; margins are in the same range as CPVC Resin.
- Chlorine integration deepening: In-house chlorine consumption is currently 65-70%; as additional CPVC resin and Chlorotoluene capacities are commissioned, consumption will rise to ~85% in two to three years, reducing merchant chlorine exposure.
- Chloromethane and Hydrogen Peroxide steady: Both products running at near 100% utilization, same as last year; realizations at ~₹30,000-32,000 for CMS and ~₹25,000-26,000 for H2O2.
Chlorotoluene: The Next Bet
- First-of-its-kind chemistry in India: No other domestic producer exists for this value chain; the product is entirely imported from China, Japan and Europe. The first phase targets 10 specific products from the broader value chain.
- Import substitution runway: Market volume is increasing YoY as custom manufacturing companies in India grow and divert molecules to Indian suppliers; multinationals in agro and pharma want a complete supply chain alternative to China.
- Customer approval timeline: Domestic approvals will come fast; export approvals will take six to nine months. Management expects to reach more than 60% of capacity including derivatives by end of FY25.
- Project commissioning: Two projects at 85% and 90% completion will be finished by end of Q4; no revenue is expected in the current financial year.
- Returns expectation: Once optimum plant capacity is reached, better realization from the product range is expected; the CapEx-to-turnover ratio for new projects is targeted at 1.4 to 1.5.
Maulik Patel: "So, we believe that this market is going to increase in next 5 to 10 years' time and completely as a Make in India, people don't need to depend on other part or the third part of the world, and all the multinationals who are in the agro or pharma they also believe and they also need a complete value chain from, and as a second option other than the China country people need completely value, entire supply chain from India."
Epichlorohydrin Dynamics
- Three demand engines: ECH consumption is growing fast driven by automobile, infrastructure, and windmill/renewable energy sectors. Domestic consumption is expected to reach ~180,000 tons in two years, possibly earlier.
- Domestic preference structural: As domestic capacity increases, domestic vendors will be first preference due to logistical challenges of importing liquid bulk raw material with storage issues.
- Antidumping application pending: An application has been filed for ECH and is under process; no timeline is known for a government decision.
- Technology barrier real: CPVC technology is not openly available like PVC; it requires R&D investment in both engineering and chemistry, and PVC and CPVC are completely different technologies.
Maulik Patel: "First of all, the CPVC is not like a PVC kind of technology which is available openly for setting up the plant. This is one first requirement."
Margins & Financials
- Sequential margin recovery: EBITDA margin improved to 26% in Q3 from 23% in Q2, driven by higher overall capacity utilization, increased CPVC and Epichlorohydrin volumes, and efficiency improvements.
- PAT leverage on flat revenue: On a QoQ basis revenue was almost flat but PAT increased 29%, attributed to diversified expansion strategies.
- Utilization sensitivity: If capacity utilization drops below 40-50%, margins will decline or hit breakeven; above that threshold, better margins can be earned.
- Debt at inflection point: Current debt of ~₹940 crore is at its peak; CapEx completing this year will start contributing cash flows from next year. Debt increased ₹80 crore while ₹323 crore CapEx was spent, with ₹250 crore funded from internal accruals.
- Cash flow allocation: In a full year with all capacities commissioned, cash flow from operations is expected around ₹500 crore; after ~₹300 crore of annual CapEx, the balance can be used for dividends and debt reduction.
Milind Kotecha: "Considering the current debt that we have all put together is around INR 940 crore, working capital and the long-term debt. So, that is a peak debt that we have, that debt will, down the line might reduce from here on."
Strategy & Long-Term Outlook
- Specialty mix shift accelerating: The 42% revenue contribution from derivatives and specialty will further increase as all future expansion plans are directed towards the derivatives and specialty segment.
- Capital allocation anchored to returns: Every project is evaluated with a 25% ROCE target kept in mind, though actual outcomes depend on market and demand scenarios.
- R&D foundation laid: An R&D center near Ahmedabad has been established; the first phase is complete and new chemistry work is ongoing, with a focus on chemistry already available and potential additions around existing strengths.
- CPVC adoption tailwind in India: CPVC was introduced in India in 2004; plumbers find it easier to handle and install than PPR for hot water pipes, driving rapid adoption. Indian authorities are expected to change specifications for fire and sprinkler applications, which would further increase CPVC resin usage.
- Medium-term guidance intact with caveat: The medium-term target (mid-2026 or 2027) may not be exactly the same number, but plus or minus 10-15% from that level; CapEx is being done keeping the target in mind and those numbers can be achieved in the next three years.
Kaushal Soparkar: "Good evening. I would like to convey that long-term story of India remains intact and current situation is short-term and looking at the Indian consumer story we are positive about long-term outlook, and we are working towards that through our future expansion and diversification in terms of multi-product catering various industries, we are targeting consistent growth both at top line and bottom line."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| CPVC Resin new capacity ramp-up | Optimum utilization level | By end of H1 FY25 |
| CPVC compound utilization | ~50% of 35,000-ton capacity | By end of H1 FY25 |
| Chlorotoluene capacity utilization | More than 60% of capacity including derivatives | By end of FY25 |
| Chlorotoluene import substitution | 15,000 tons capacity targeting 10 products currently imported | By FY2026 |
| In-house chlorine consumption | Reach ~85% | In 2-3 years |
| Medium-term revenue target | Plus or minus 10-15% from previously guided number | In next 3 years |
| Annual sustaining CapEx | ~₹300-350 crore per year | Ongoing |
| Project completion (two near-complete) | 85% and 90% complete projects finished | By end of Q4 FY24 |
Key Metrics
| Metric | Q3 FY24 |
|---|---|
| Revenue | ₹472 cr, flat QoQ, down 14% YoY |
| EBITDA | ₹123 cr, up 14% QoQ |
| EBITDA margin | 26%, up from 23% in Q2 FY24 |
| PAT | ₹49 cr, up 29% QoQ |
| PAT margin | 10%, up from 8% in Q2 FY24 |
| Volume growth | 18% YoY in Q3 FY24, 17% for nine months FY24 |
| Derivative & specialty revenue share | 42% in nine months FY24, up from 27% in nine months FY23 |
| Overall capacity utilization | 81%, up from 77% in Q2 FY24 |
| Net debt | ₹944 cr as on 31 Dec 2023, up ₹81 cr from 31 Mar 2023 |
| Net debt to EBITDA | 1.96x, up from 1.83x in Q2 FY24 |
| Net debt to equity | 0.8x, down from 0.85x in Q2 FY24 |
| Return on capital employed (trailing 12M) | 18% including CWIP, 21% excluding CWIP |
| Epichlorohydrin capacity utilization | 55%–60%, up from 40%–45% in Q2 FY24 |
| CPVC Resin capacity utilization | ~85% |
| Chlor-Alkali capacity utilization | 78%–80%, up from ~75% in Q2 FY24 |
| ECU realization | ₹27,000–₹28,000 |
| Caustic soda realization | ₹31,000–₹32,000 |
| Epichlorohydrin realization | ₹1,00,000–₹1,05,000 |
| Epichlorohydrin export share | 30%–35% |
| In-house chlorine consumption | 65%–70%, expected to reach ~85% in 2–3 years |
| CPVC Resin realization | ~₹140 (per kg) |
| Hydrogen Peroxide realization | ~₹25,000–₹26,000 |
| Chloromethane realization | ~₹30,000–₹32,000 |
| Cash outflow for capital expenditure (9M FY24) | ₹323 cr, with ~₹250 cr funded from internal accruals |
| Long-term debt | ~₹640 cr out of ₹944 cr total debt |
| Annual debt repayment schedule | ~₹180 cr |
| Redeemable preference shares outstanding | ₹120 cr as on 31 Dec 2023, down from peak of ₹211 cr |
| Annual continuous CapEx range | ₹300–₹350 cr |
| India CPVC Resin volume expectation by 2030 | ~5 lakh tons |